
Patients with certain inflammatory and senescence markers appeared to progress more quickly in their Parkinson disease, according to new research.

Patients with certain inflammatory and senescence markers appeared to progress more quickly in their Parkinson disease, according to new research.

Patients with high-risk multiple myeloma tend to have significantly worse prognoses compared to those in the standard-risk category. A new study offers a potential solution.

A major study of patients with osteosarcoma suggests new pathogenic and likely pathogenic germline variants associated with the bone cancer.

Limited data about the effects of psoriasis therapy during pregnancy make it difficult to know which options are possible for pregnant patients and which ones can be harmful, according to a review.

Clinical trials for biosimilars and other agents are likely to slow down, if not stall, as coronavirus disease 2019 (COVID-19) wends its course, according to a UT Health expert.

Pregnancy complications that include preeclampsia, gestational hypertension, pre-term birth, and low birthweight serve as possible indicators for greater risk of heart failure in the long term, as indicated by change in global longitudinal strain on echocardiogram.

This week, the top managed care news includes a $2 trillion package to address economic damage from coronavirus heads to President Trump, a regulatory change could change the fortunes for biosimilars, and the world’s biggest cardiology meeting goes virtual.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

An expert panel discussed the systemic and policy barriers to the uptake of biosimilars.

Ovarian cancer remains the most deadly of the gynecologic cancers. Researchers from Dana-Farber Cancer Institute may have discovered biomarkers that could predict which patients with platinum-resistant ovarian cancer would benefit from combination poly-ADP ribose polymerase (PARP) inhibitor/immune checkpoint inhibition treatment, as well as those who should pursue a different course of therapy.

Investigators used virtual reality to better understand the particular vision difficulties of patients with glaucoma.

Ibrutinib has been successful at fighting chronic lymphocytic leukemia (CLL), but new research finds interruptions in treatment with the drug can have a negative impact on patient outcomes.

A new study reveals severe depression in minority patients; Louisiana faces a surge of COVID-19 cases; New York state adjusts its medical workforce to combat rising cases.

Using a smartphone was associated with higher usage of acute medication, but less relief, in individuals with new-onset headache or increased severity of headache.

The bill includes $100 billion for hospitals; some are concerned that the bill, the Coronavirus Aid, Relief, and Economic Security (CARES) Act, does not go far enough, particularly for Medicaid.

According to the CDC, individuals with diabetes may experience more serious complications from the novel coronavirus (COVID-19) than the general population.

The FDA has accepted for filing with priority review Jazz Pharmaceuticals’ new drug application for JZP-258. The investigational medicine targets cataplexy and excessive daytime sleepiness associated with narcolepsy.

Not all women with dense breast tissue have a high risk of breast cancer, but they all have an increased risk compared with women who have average tissue density. Can this patient population benefit from screening with abbreviated breast magnetic resonance imaging (AB MRI) over digital breast tomosynthesis?

During the coronavirus disease 2019 (COVID-19) pandemic, Innovaccer’s free to use COVID-19 Management System promotes the ability for patients to implement self-assessments to determine severity risk, which could prove crucial in at-risk, under resourced populations.

The FDA approved Bristol Myers Squibb’s ozanimod (Zeposia) 0.92 mg as an oral treatment for relapsing forms of multiple sclerosis (RMS). Ozanimod can be used to treat clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Horizon Blue Cross Blue Shield has temporarily waived its "actively at work" requrement for group policies; Native American populations, some of the nation's most vulerable, are ill-equipped to respond to the COVID-19 pandemic; rates of sexually transmitted infections increase among pregnant women.

Thomas C. Corbridge, MD, FCCP, is a GSK medical expert and an emeritus physician and adjunct professor of medicine at Northwestern University, Feinberg School of Medicine in Chicago, Illinois. Dr. Corbridge received his medical degree from the University of Chicago Pritzker School of Medicine and has been in practice for over 30 years. Dr. Corbridge specializes in pulmonary and critical care medicine and is experienced in asthma, chronic obstructive pulmonary disease and general pulmonology.

Extending school and workplace closures in Wuhan until April would likely delay a second wave of coronavirus disease 2019 (COVID-19) cases until October, rather than August, and cut new infections by 24%, said a recent report.

“The brunt of COVID-19 will be borne by the poor, elderly, and sick, and it is up to us to ensure they are not left behind” – Former US Surgeon General Vivek Murthy

Evidence is considered lacking on the association between mortality and patients who have both cardiac injury and coronavirus disease 2019 (COVID-19). Is the rate of death higher among these patients compared with patients without cardiac disease who have COVID-19?

The FDA issues safety alerts for EpiPen and EpiPen Jr Auto-Injectors; we should be drinking more water to reduce the effects of increased sugar intake; experts suggest actively working to protect mental health while on lockdown.

The FDA called it “a historic day” as insulin and certain other biologic drugs transitioned to a different regulatory pathway.

The FDA Tuesday cleared a new dose of Samsung Bioepis’ trastuzumab biosimilar Ontruzant, which is yet to be launched in the United States. The approval is for a 420-mg multidose vial of Ontruzant. The biosimilar was first approved as a 150-mg single-dose vial by the FDA in January 2019 across all indications for the reference product, Herceptin.

Researchers were able to effectively use an arm-mounted optical coherence tomography angiography (OCTA) device to learn information about the developing fovea in extreme low birth weight (ELBW) neonates, according to a study published in the American Journal of Ophthalmology.

Researchers at the University of North Carolina School of Medicine found that falls simulated through virtual reality could enable early detection of balance problems in patients with multiple sclerosis (MS), according to a study published in PLoS One.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
